Business Context and Reporting Period
Company: NeOnc Technologies Holdings, Inc. (NTHI)
Filing Type: Form 8-K (Current Report)
Date of Report: March 4, 2026
Reporting Period: Event-based disclosure regarding clinical trial data.
Business Context: The Company is an emerging growth company focused on oncology. This filing discloses the release of data from the dose-escalation portion of its Phase 1/2 clinical trial for its candidate drug, NEO212.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K is a disclosure of a material event (clinical data release) rather than a periodic financial report (10-K or 10-Q).
Material Changes
Clinical Development Update: On March 4, 2026, the Company announced data from the dose-escalation portion of the Phase 1/2 clinical trial for NEO212. This represents a material development in the Company's pipeline, though specific efficacy or safety metrics are contained in the attached press release (Exhibit 99.1) and not summarized in the body of this 8-K.
Guidance, Outlook, and Management Commentary
- Management Action: The Company hosted an investor conference call on March 4, 2026, to discuss the clinical data.
- Exhibits: The filing includes the press release (Exhibit 99.1), the investor presentation (Exhibit 99.2), and the call transcript (Exhibit 99.3).
- Legal Disclaimer: The information in Item 7.01 and the associated exhibits is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference into other filings unless expressly stated.
- Guidance: The filing text does not contain updated financial guidance or specific future outlook statements beyond the discussion of the clinical data.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific details on the safety and tolerability results of the NEO212 dose-escalation trial.
- Examine Exhibit 99.2 (Investor Presentation) for management's interpretation of the data and potential next steps for the trial.
- Check Exhibit 99.3 (Transcript) for Q&A responses regarding the timeline for dose-expansion or subsequent trial phases.
- Verify the Company's cash runway and liquidity status in the most recent 10-Q or 10-K, as this 8-K does not contain updated financial statements.